Hyposens

Hyposens answers the call for Information and Communication Technologies. The topics addressed in this Work Programme part promote more innovation-orientation to ensure that the EU industry remains strong in the core technologies that are at the roots of future value chains.

With HypoSens we developed a non-invasive and crucial prognostic tool for breast cancer progression in early stages to help clinicians and specially oncologists to decide about prompt therapy approaches to patients and improve quality of life and expectancy. HypoSens prognostic system consists of a non-invasive Near-infrared imaging device able to register signals through scattering media enabled by the implementation of wave front shaping, that process data collected by injected tumor-targeted body antibody functionalized nano-particles containing porphyrin sensors that determine local oxygen concentration and local temperature distribution in the cancer cells. The HypoSens imaging system is strategically designed to offer a non-invasive alternative to the Sentinel Lymph Node Biopsy, the current surgical procedure for breast cancer staging. The device is an affordable, accurate, easy to use prognostic solution for clinicians towards more accurate and fast diagnostics and personalized treatment options.

With an estimated 1.7 million new cases each year, breast cancer is the most common cancer among women worldwide. Its low cost will enable a wide and fast take-up by clinicians and hospitals leading to an important reduction of the economic and societal burden related to the diagnosis and treatment of cancer.

Find the latest information on the Hyposens Project website!


Stay up-to-date with the Horizon 2020 updates. Sign up for our newsletter!

Subscribe to our Newsletter